checkAd

    DGAP-News  505  0 Kommentare Carl Zeiss Meditec AG grows in all business units - Seite 3



    Outlook

    Over the past few months ZEISS has enriched the medical technology industry
    with a number of significant product innovations. The CT LUCIA, for
    example, an intraocular lens for the standard segment, which is
    manufactured at the new Aaren Scientific Inc. site in Ontario (California),
    was launched in September 2014. The optical biometry portfolio was also
    expanded in September, with the IOLMaster 700. This is a new product
    generation, which also includes the highly innovative, integrated SWEPT
    Source OCT technology. Ludwin Monz: "Our company has a strong product
    portfolio. We have also been able to set new benchmarks in the market with
    the successful launch of our new products. We are optimistic in the current
    financial year that we will be able to further strengthen our market
    position. As announced, our EBIT margin is also expected to remain within
    the projected range of 13 to 15 percent throughout the course of the year.


    Revenue by strategic business unit 1

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Carl Zeiss Meditec AG!
    Long
    88,26€
    Basispreis
    0,75
    Ask
    × 12,68
    Hebel
    Short
    102,62€
    Basispreis
    0,81
    Ask
    × 11,74
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Figures in EUR'000 3 Months 3 Months Change from
    2013/14 2014/15 previous year


    Ophthalmic Systems 80,817 91,742 + 13.5%


    Surgical Ophthalmology 66,665 81,570 + 22.4%


    Microsurgery 64,797 67,778 + 4.6%

    1 For better comparability the previous year's figures have been adjusted
    in line with the new structure.


    Revenue by region


    Figures in EUR'000 3 Months 3 Months Change from

    2013/14 2014/15 previous year


    EMEA 70,522 86,549 22.7 %


    Americas 77,568 80,639 4.0 %


    APAC 64,189 73,902 15.1 %




    Press contact:
    Jann Gerrit Ohlendorf
    Director Corporate Communications Carl Zeiss Meditec AG
    Phone +49 (0)3641 220-331
    E-mail: press.meditec@zeiss.com

    Investors contact:
    Sebastian Frericks
    Director Investor Relations Carl Zeiss Meditec AG
    Phone: +49 (0)3641 220-116
    E-mail: investors.meditec@zeiss.com
    www.zeiss.de/presse





    ---------------------------------------------------------------------

    11.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    Language: English
    Company: Carl Zeiss Meditec AG
    Göschwitzer Str. 51-52
    07745 Jena
    Germany
    Phone: +49 (0)3641 220-0
    Fax: +49 (0)3641 220-112
    E-mail: investors.meditec@zeiss.com,info.meditec@zeiss.com
    Internet: www.meditec.zeiss.de
    ISIN: DE0005313704
    WKN: 531370
    Listed: Regulierter Markt in Frankfurt (Prime Standard);
    Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
    München, Stuttgart


    End of News DGAP News-Service
    ---------------------------------------------------------------------
    321851 11.02.2015
    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte

    Aktuelle Themen


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Carl Zeiss Meditec AG grows in all business units - Seite 3 DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarter Results Carl Zeiss Meditec AG grows in all business units 11.02.2015 / 07:00 --------------------------------------------------------------------- Carl Zeiss Meditec AG grows in all business …

    Schreibe Deinen Kommentar

    Disclaimer